PharmaBlock Sciences (Nanjing), Inc. (SZSE:300725) is a leading provider of innovative chemistry products and services throughout the pharmaceutical R&D and commercial production. Its core businesses include: a catalog of specially designed scaffolds and building blocks; custom synthesis; process development; manufacturing of key intermediates and RSMs.
Officially operated in 2008, PharmaBlock has rapidly gained recognition for its outstanding capability in the design, synthesis, and supply of novel building blocks for drug discovery use. Upon daily monitoring recent researches and patents in drug R&D and medicinal chemistry, the product portfolio keeps expanding.
With more drug R&D projects applying the company’s products advance from discovery to preclinical and clinical research, even into commercialization, PharmaBlock moved on to build up top notch process R&D capabilities, and is providing scale-up synthesis and manufacturing of building blocks and GMP/non-GMP intermediates. It is planning to establish the API capabilities in 2019. The company has two manufacturing sites at Shangyu, Zhejiang Province and Dezhou, Shandong Province, with around 250 cu.meter combined reactor volume, ranging from 200L to 6,300L of reactor size. The company is now committed to a more comprehensive and long-term service to valued customers.
Over the past years, PharmaBlock has partnered with over 80% of the top 20 pharmaceutical companies, and hundreds of small to medium-sized biotechs around the world. In 2012, the company opened a facility in San Francisco Bay Area, and set up the United States headquarters in Pennsylvania in 2017, expanding the inventory, customer service and lab functions for more efficient and timely services to local customers in the United States and Europe.